ALN-PNP and GLP-1 Agonist Combo Explored for Genetic Fatty Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), commonly known as fatty liver disease, affects millions globally and can progress to severe liver damage. A specific genetic variant in the PNPLA3 gene (Patatin-like phospholipase domain-containing protein 3) is a major risk factor for more aggressive forms of MASLD. Current treatments often focus on lifestyle changes, but there's a significant unmet need for targeted pharmacological therapies, especially for genetically predisposed individuals. This study aims to evaluate if ALN-PNP, alone or with a GLP1R agonist, can effectively reduce liver fat in patients with homozygous PNPLA3-related MASLD.

As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, there are no actual findings to report yet. However, the primary objective is to assess the ability of ALN-PNP to reduce liver fat in patients with homozygous PNPLA3-related MASLD. Researchers will specifically evaluate changes in liver fat content, likely measured by non-invasive imaging techniques, comparing treatment arms against placebo. The study also aims to determine if combining ALN-PNP with a GLP1R agonist like Tirzepatide offers superior benefits in liver fat reduction and other metabolic markers. The central goal is to establish whether ALN-PNP, a novel therapeutic targeting the PNPLA3 protein, can significantly decrease liver fat in this specific patient population, potentially offering a new treatment pathway for a challenging form of MASLD. Secondary objectives will likely include evaluating safety, tolerability, and effects on other markers of liver health and metabolic function across the various treatment groups, involving an estimated 204 participants.